MOLTALL

Molecularly targeted therapy for T cell acute lymphoblastic leukemia

Coordinatore	VIB    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Belgium [BE]
Totale costo	1˙384˙632 €
EC contributo	1˙384˙632 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2007-StG
Funding Scheme	ERC-SG
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-10-01   -   2013-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	VIB  Organization address address: Rijvisschestraat 120 city: ZWIJNAARDE - GENT postcode: 9052 contact info Titolo: Mr. Nome: Rik Cognome: Audenaert Email: send email Telefono: 3292446611 Fax: 3292446610	BE (ZWIJNAARDE - GENT)	hostInstitution	0.00
2	VIB  Organization address address: Rijvisschestraat 120 city: ZWIJNAARDE - GENT postcode: 9052 contact info Titolo: Prof. Nome: Jan Cognome: Cools Email: send email Telefono: 3216330082 Fax: 3216330084	BE (ZWIJNAARDE - GENT)	hostInstitution	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'T cell acute lymphoblastic leukemia (T-ALL) is an aggressive T cell malignancy that is most common in children and adolescents. Our current understanding of the molecular genetics of T-ALL indicates that leukemic transformation of thymocytes is caused by the cooperation of mutations that affect proliferation, survival, cell cycle, differentiation and self renewal. Molecular analysis has identified a large number of T-ALL specific oncogenes, but the genetic defects that are implicated in the aberrant proliferation and survival of the leukemic cells remain largely unknown. It is the aim of this project to continue the molecular characterization of T-ALL using genome wide analyses, focused RNAi screens, and drug library screens to identify oncogenes that specifically provide proliferation and survival advantages, as well as other targets for therapy in T-ALL. In addition, we will study the cooperation of these oncogenes with other oncogenic events using in vitro and in vivo mouse models, and use those models for the development and characterization of novel therapeutics. This project will generate novel insights in the molecular pathogenesis of T-ALL and aims at translating this information towards novel targeted therapies.'